Now for patients with steroid-resistant FSGS, the mTORC1/4E-BP1-signaling inhibitor, rapamycin, also known as sirolimus, has been used to ameliorate FSGS progression through antiproliferation, suppression of podocyte immune responses, and activation of autophagy45–47. The gene discussed is EIF4EBP1; the disease is focal segmental glomerulosclerosis.